SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)
Name:
mdz394.070.pdf
Size:
100.3Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract
Authors
Nathan, PNeedham, A
Corrie, PG
Danson, S
Evans, J
Ochsenreither, S
Kumar, S
Goodman, A
Larkin, JMG
Karydis, I
Steven, NM
Lorigan, Paul C
Plummer, R
Patel, P
Shaw, HM
Leyvraz, S
Rawcliffe, C
Psarelli, EE
Handley, L
Sacco, JJ
Affiliation
Department of Medical Oncology, Mount Vernon Cancer Centre, NorthwoodIssue Date
2019
Metadata
Show full item recordCitation
Nathan P, Needham A, Corrie PG, Danson S, Evans J, Ochsenreither S, et al. LBA73SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). Annals of Oncology. 2019;30(Supplement_5).Journal
Annals of OncologyDOI
10.1093/annonc/mdz394.070Additional Links
https://dx.doi.org/10.1093/annonc/mdz394.070Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz394.070